{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:58:18Z","timestamp":1789009098371,"version":"build-2803163510"},"reference-count":106,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K22CA218466-02"],"award-info":[{"award-number":["5K22CA218466-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA199447"],"award-info":[{"award-number":["CA199447"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA208353"],"award-info":[{"award-number":["CA208353"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA068458"],"award-info":[{"award-number":["CA068458"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA210087"],"award-info":[{"award-number":["CA210087"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["17-20-46-MUND"],"award-info":[{"award-number":["17-20-46-MUND"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-20-051-01-LIB"],"award-info":[{"award-number":["RSG-20-051-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Over the past 50 years, few therapeutic advances have been made in treating acute myeloid leukemia (AML), an aggressive form of blood cancer, despite vast improvements in our ability to classify the disease. Emerging evidence suggests the immune system is important in controlling AML progression and in determining prognosis. Natural killer (NK) cells are important cytotoxic effector cells of the innate lymphoid cell (ILC) family that have been shown to have potent anti-leukemic functions. Recent studies are now revealing impairment or dysregulation of other ILCs in various types of cancers, including AML, which limits the effectiveness of NK cells in controlling cancer progression. NK cell development and function are inhibited in AML patients, which results in worse clinical outcomes; however, the specific roles of other ILC populations in AML are just now beginning to be unraveled. In this review, we summarize what is known about the role of ILC populations in AML.<\/jats:p>","DOI":"10.3390\/cancers13020320","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T05:17:34Z","timestamp":1610947054000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7108-9765","authenticated-orcid":false,"given":"Matthew R.","family":"Lordo","sequence":"first","affiliation":[{"name":"Biomedical Sciences Graduate Program, Medical Scientist Training Program, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Scoville","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Department of Surgery, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akul","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0326-3223","authenticated-orcid":false,"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon G.","family":"Freud","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Caligiuri","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany L.","family":"Mundy-Bosse","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41375-020-0916-8","article-title":"Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality","volume":"34","author":"Issa","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Estey","year":"2010","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML","volume":"24","author":"Carlsten","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/bloodadvances.2018030478","article-title":"CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML","volume":"3","author":"Salome","year":"2019","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3389\/fimmu.2019.02180","article-title":"The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype","volume":"10","author":"Cuff","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: You can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","article-title":"Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function","volume":"132","author":"Scoville","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fimmu.2017.00573","article-title":"Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fimmu.2015.00564","article-title":"Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia","volume":"6","author":"Chretien","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1307491","DOI":"10.1080\/2162402X.2017.1307491","article-title":"NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML","volume":"6","author":"Chretien","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49548","DOI":"10.18632\/oncotarget.17747","article-title":"NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.3324\/haematol.2014.119602","article-title":"CD127+ innate lymphoid cells are dysregulated in treatment na\u00efve acute myeloid leukemia patients at diagnosis","volume":"100","author":"Trabanelli","year":"2015","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wu, L., Lin, Q., Ma, Z., Chowdhury, F.A., Mazumder, M.H.H., and Du, W. (2020). Mesenchymal PGD(2) activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia.","DOI":"10.1038\/s41375-020-0843-8"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","article-title":"Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis","volume":"8","author":"Trabanelli","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2013-11-536888","article-title":"Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease","volume":"124","author":"Munneke","year":"2014","journal-title":"Blood"},{"key":"ref_36","first-page":"1861","article-title":"Autologous natural killer cell therapy for human recurrent malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2005.01.013","article-title":"A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells","volume":"22","author":"Freud","year":"2005","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2014.02.008","article-title":"Human natural killer cell development in secondary lymphoid tissues","volume":"26","author":"Freud","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2013.07.005","article-title":"Location and cellular stages of natural killer cell development","volume":"34","author":"Yu","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.cell.2017.02.021","article-title":"Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CJI.0000000000000171","article-title":"Significance of Frequencies, Compositions, and\/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL","volume":"40","author":"Boeck","year":"2017","journal-title":"J. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Bai","year":"2007","journal-title":"Blood"},{"key":"ref_43","first-page":"5497","article-title":"Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ng.923","article-title":"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)","volume":"43","author":"Ostergaard","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2012-09-453969","article-title":"Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset","volume":"121","author":"Mace","year":"2013","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/bjc.1988.221","article-title":"Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission","volume":"58","author":"Pizzolo","year":"1988","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1990.tb05241.x","article-title":"Loss of natural killer activity as an indicator of relapse in acute leukaemia","volume":"80","author":"Tratkiewicz","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2002.03495.x","article-title":"Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells","volume":"117","author":"Lowdell","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.21906","article-title":"Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission","volume":"86","author":"Dauguet","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","article-title":"Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors","volume":"59","author":"Szczepanski","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful Transfer of Umbilical Cord Blood CD34(+) Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/cti.2014.11","article-title":"Adoptive T-cell therapy: Adverse events and safety switches","volume":"3","author":"Tey","year":"2014","journal-title":"Clin. Transl. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/bloodadvances.2019000242","article-title":"Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Zhao","year":"2019","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2019001284","article-title":"Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia","volume":"4","author":"Verneris","year":"2020","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_58","first-page":"2515135520927164","article-title":"CAR T-cell immunotherapy of B-cell malignancy: The story so far","volume":"8","author":"Halim","year":"2020","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_60","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Denman, C.J., Senyukov, V.V., Somanchi, S.S., Phatarpekar, P.V., Kopp, L.M., Johnson, J.L., Singh, H., Hurton, L., Maiti, S.N., and Huls, M.H. (2012). Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030264"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2019-128005","article-title":"BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)","volume":"134","author":"Vasu","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.immuni.2015.09.013","article-title":"Natural Killer Cell Memory","volume":"43","author":"Sun","year":"2015","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/nm1312","article-title":"Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2017.09.052","article-title":"ILC1 Confer Early Host Protection at Initial Sites of Viral Infection","volume":"171","author":"Weizman","year":"2017","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.it.2019.08.005","article-title":"True Detective: Unraveling Group 1 Innate Lymphocyte Heterogeneity","volume":"40","author":"Riggan","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.4049\/jimmunol.178.8.4947","article-title":"CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation","volume":"178","author":"Romagnani","year":"2007","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.181.3.2227","article-title":"An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation","volume":"181","author":"Dulphy","year":"2008","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2013-11-427781","article-title":"Human innate lymphoid cells","volume":"124","author":"Hazenberg","year":"2014","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/cas.12459","article-title":"Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia","volume":"105","author":"Han","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17-Producing Cells in Tumor Immunity: Friends or Foes?","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune Netw."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.1222551","article-title":"Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria","volume":"336","author":"Sonnenberg","year":"2012","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.immuni.2012.05.028","article-title":"Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease","volume":"37","author":"Hanash","year":"2012","journal-title":"Immunity"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.celrep.2014.05.042","article-title":"The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells","volume":"8","author":"Hughes","year":"2014","journal-title":"Cell Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.immuni.2011.07.009","article-title":"MicroRNA-29 regulates T-box transcription factors and interferon-\u03b3 production in helper T cells","volume":"35","author":"Steiner","year":"2011","journal-title":"Immunity"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4049\/jimmunol.1103171","article-title":"miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis","volume":"189","author":"Smith","year":"2012","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1182\/blood-2009-03-211938","article-title":"MicroRNA 29b functions in acute myeloid leukemia","volume":"114","author":"Garzon","year":"2009","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/cdd.2013.133","article-title":"The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia","volume":"21","author":"Gong","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1089\/scd.2014.0597","article-title":"The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells","volume":"24","author":"Roeven","year":"2015","journal-title":"Stem Cells Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ni.2187","article-title":"AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch","volume":"13","author":"Lee","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.20151998","article-title":"The aryl hydrocarbon receptor is required for the maintenance of liver-resident natural killer cells","volume":"213","author":"Zhang","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.immuni.2018.09.015","article-title":"Aryl Hydrocarbon Receptor Signaling Cell Intrinsically Inhibits Intestinal Group 2 Innate Lymphoid Cell Function","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12391","DOI":"10.1073\/pnas.1302856110","article-title":"Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor","volume":"110","author":"Shin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/eji.201747289","article-title":"The aryl hydrocarbon receptor modulates the function of human CD56(bright) NK cells","volume":"48","author":"Mundy","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","article-title":"Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals","volume":"43","author":"Denison","year":"2003","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1124\/mol.109.061788","article-title":"Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity","volume":"77","author":"Murray","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Adams, S., Teo, C., McDonald, K.L., Zinger, A., Bustamante, S., Lim, C.K., Sundaram, G., Braidy, N., Brew, B.J., and Guillemin, G.J. (2014). Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112945"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR Pathway for Cancer Immunotherapy\u2014Challenges and Opportunities","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","article-title":"Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"56","author":"Fukuno","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.4049\/jimmunol.1601711","article-title":"Fate Decision Between Group 3 Innate Lymphoid and Conventional NK Cell Lineages by Notch Signaling in Human Circulating Hematopoietic Progenitors","volume":"199","author":"Kyoizumi","year":"2017","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/eji.201242639","article-title":"Transcriptional control of innate lymphoid cells","volume":"42","author":"Bernink","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3389\/fimmu.2018.01252","article-title":"The Notch Signaling Pathway Is Balancing Type 1 Innate Lymphoid Cell Immune Functions","volume":"9","author":"Perchet","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nalin, A.P., Kowalski, J.J., Sprague, A.C., Schumacher, B.K., Gerhardt, A.G., Youssef, Y., Vedantam, K.V., Zhang, X., Siebel, C.W., and Mace, E.M. (2020). Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. J. Immunol.","DOI":"10.4049\/jimmunol.2000434"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.20121527","article-title":"Notch activation inhibits AML growth and survival: A potential therapeutic approach","volume":"210","author":"Kannan","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1158\/1078-0432.CCR-19-2479","article-title":"EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia","volume":"26","author":"Bill","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41577-020-0282-9","article-title":"Plasticity of innate lymphoid cell subsets","volume":"20","author":"Bal","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Bald, T., Wagner, M., Gao, Y., Koyasu, S., and Smyth, M.J. (2019). Hide and seek: Plasticity of innate lymphoid cells in cancer. Semin. Immunol.","DOI":"10.1016\/j.smim.2019.04.001"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ni.3800","article-title":"Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells","volume":"18","author":"Gao","year":"2017","journal-title":"Nat. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:12:04Z","timestamp":1760159524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":106,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cancers13020320"],"URL":"https:\/\/doi.org\/10.3390\/cancers13020320","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,17]]}}}